News and Trends 17 Oct 2022 Clinical Microbiomics acquires MS-Omics Clinical Microbiomics, a microbiome research company, has acquired MS-Omics, a metabolomics provider based in Denmark. Clinical Microbiomics works on clonal-level microbiome profiling. With the acquisition, Clinical Microbiomics adds expertise in metabolite profiling from MS-Omics to further advance its systems biology platform and help researchers worldwide understand the microbiome and how to impact health and disease. […] October 17, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 More positive news announced for Verona’s COPD treatment Clinical-stage biopharmaceutical company, Verona, has announced more positive news from its phase 3 ENHANCE-2 clinical trial of ensifentrine that treats chronic obstructive pulmonary disease (COPD). The company focuses on respiratory diseases, and made the announcement today (October 14) about the positive analyses demonstrating how ensifentrine reduced exacerbation rates across subgroups in the trial. Ensifentrine is […] October 17, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 Way to transform Cas-9 protein into spherical nuclear acid developed A team of researchers at U.S. Northwestern University has developed a way to transform the Cas-9 protein into a spherical nuclear acid (SNA). It can then be loaded with critical components as required to access a broad range of tissue and cell types, as well as the intracellular compartments required for gene editing. The team […] October 17, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 Italian study shows CRISPR/Cas9 deletion of Interleukin-30 reduces prostate cancer growth Metastatic prostate cancer is a leading cause of cancer death in men worldwide. Interleukin (IL)-30, a cytokine that may perform immunomodulatory functions, promotes prostate cancer onset and development, but whether it can be a suitable therapeutic target remains to be investigated. In a new study published in the Journal of Hematology & Oncology, researchers at […] October 17, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 PerkinElmer’s Horizon Discovery: the lowdown on base editing PerkinElmer’s Horizon Discovery provides cell engineering tools and services for researchers in drug discovery and development. Horizon’s portfolio is focused on research reagents; screening and cell line engineering services; bioproduction cell lines; reference standards and base editing. Horizon’s base editing platform, Pin-point is a gene editing method with the ability to effect multiple single base edits […] October 17, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 The challenges of translating CRISPR to the clinic CRISPR-Cas9 is revolutionizing all facets of drug discovery, allowing for both a deeper understanding of disease processes, and for the development of ground-breaking genetic medicines. As these new classes of cell and gene therapies translate to the clinical setting, some key bottlenecks remain to be solved before the technology will realize its full societal impact. […] October 17, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 CRISPR/Cas9: Challenges and outlook from an investor’s perspective A Q&A with Fady Riad, CEO of consulting company Centurion Life Sciences. How did CRISPR/Cas9 revolutionize gene editing and the broader life sciences industry? CRISPR/Cas9 is undoubtedly one of the greatest scientific advancements of the last 100 years. In 2012, Jennifer Doudna and Emanuelle Charpentier published a peer-reviewed paper discussing the use of CRISPR/Cas9 in […] October 17, 2022 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
More News! 14 Oct 2022 ChristianaCare spins out new gene-editing company CorriXR Therapeutics ChristianaCare has spun out its first commercial biotech private start-up company, CorriXR Therapeutics. CorriXR Therapeutics will use CRISPR gene editing technology to develop new, clinically relevant oncologic therapeutics in areas of unmet medical need, starting with squamous cell carcinoma of the lung. Its close relationship with ChristianaCare and the ChristianaCare Gene Editing Institute positions it […] October 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Oct 2022 Cytel signs agreement with two Scandinavian medicinal product companies U.S.-based Cytel Inc. has entered into an agreement to acquire Scandinavian companies SDS Life Sciences AB and SDS MedeQ AB. Cytel says the move will add new talent to the company’s strategic consulting group and bring additional capabilities for the development of drugs and medical devices. It says sponsors will also have easier access to […] October 14, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 14 Oct 2022Beyond Biotech podcast 18: BiotechX, Cultivated Biosciences, EPFL, Faron Pharmaceuticals This week, we have four interviews. Our guests are: Juho Jalkanen, COO of Faron Pharmaceuticals; Ardemis Boghossian and Melania Reggente from the EPFL School of Basic Sciences in Switzerland; Tomas Turner, CEO and co-founder of Cultivated Biosciences; and Joanna Magaji, conference manager for the BiotechX event. BiotechX event taking place in Basel in November BiotechX, […] October 14, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 14 Oct 2022 Danish researchers create ‘Wikipedia of resistant bacteria’ According to the WHO, antibiotic resistance is one of the biggest threats to public health. Researchers at DTU in Denmark have created a new tool in the fight against resistant bacteria that, based on 214,000 microbiome samples, can create an overview of the problem across countries, people and environments. In the future, even a small […] October 14, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Oct 2022 Mablink Bioscience receives €31M series A funding for ADC pipeline French biotech company Mablink Bioscience has raised €31 million ($30.3 million) in series A funding to advance its lead candidate to the clinic and to build a pipeline of antibody drug conjugates (ADCs). The round was led by Sofinnova Partners and Mérieux Equity Partners. Existing shareholders Elaia Partners, UI-Investissement/Pertinence Invest 2 (advised by Mérieux Equity […] October 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email